MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, AURA had $28,008K increase in cash & cash equivalents over the period. -$85,189K in free cash flow.

Cash Flow Overview

Change in Cash
$28,008K
Free Cash flow
-$85,189K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Proceeds from issuance of common...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Accretion income on marketable s...
    • Operating lease liabilities
    • Others

Cash Flow
2025-12-31
Net loss
-106,191
Depreciation expense
1,129
Accretion income on marketable securities
1,546
Other non-cash items
27
Stock-based compensation expense
14,317
Non-cash lease expense
1,551
Prepaid expenses and other assets
-4,031
Other long-term assets
-47
Accounts payable
-846
Accrued expenses and other liabilities
4,131
Operating lease liabilities
-1,392
Net cash used in operating activities
-84,742
Purchases of property and equipment
447
Purchases of marketable securities
83,958
Maturities of marketable securities
120,000
Net cash provided by investing activities
35,595
Proceeds from exercise of stock options
1,010
Proceeds from issuance of common stock from follow-on offering, net of issuance costs
46,517
Proceeds from issuance of pre-funded warrants from follow-on offering, net of issuance costs
14,156
Proceeds from issuance of common stock warrants from follow-on offering, net of issuance costs
9,254
Proceeds from issuance of common stock under atm facility, net of issuance costs
6,054
Proceeds from espp purchases
164
Net cash provided by financing activities
77,155
Net increase (decrease) in cash, cash equivalents and restricted cash
28,008
Effect of exchange rate changes on cash and cash equivalents
-186
Cash, cash equivalents and restricted cash at beginning of period
32,461
Cash, cash equivalents and restricted cash at end of period
60,283
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock from...$46,517K Proceeds from issuance ofpre-funded warrants from...$14,156K Proceeds from issuance ofcommon stock warrants...$9,254K Proceeds from issuance ofcommon stock under atm...$6,054K Proceeds from exercise ofstock options$1,010K Proceeds from espppurchases$164K Maturities of marketablesecurities$120,000K Net cash provided byfinancing activities$77,155K Net cash provided byinvesting activities$35,595K Canceled cashflow$84,405K Net increase(decrease) in cash, cash...$28,008K Canceled cashflow$84,742K Stock-based compensationexpense$14,317K Accrued expenses andother liabilities$4,131K Prepaid expenses andother assets-$4,031K Non-cash lease expense$1,551K Depreciation expense$1,129K Other long-termassets-$47K Other non-cash items$27K Purchases of marketablesecurities$83,958K Purchases of property andequipment$447K Net cash used inoperating activities-$84,742K Canceled cashflow$25,233K Net loss-$106,191K Accretion income onmarketable securities$1,546K Operating leaseliabilities-$1,392K Accounts payable-$846K

Aura Biosciences, Inc. (AURA)

Aura Biosciences, Inc. (AURA)